BioCentury
ARTICLE | Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Emerging Company Profile: Swiss newco is developing peptide linkers that could improve ADC’s therapeutic window

March 6, 2021 2:11 AM UTC

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers can connect antibodies to drug payloads without the need for antibody modification, resulting in ADCs that are easier to manufacture. 

ADC developers face an uphill battle when seeking the optimal combination of antibodies, linkers, and payloads for their programs, as each component comes with its own efficacy and toxicity considerations. ...

BCIQ Company Profiles

Araris Biotech AG